Regardless of the precise mechanism, the data shown here demonstrate that blocking BMP9/10 signalling induces an increase in PI3K signalling and identify PI3K signalling pathway inhibition as a putative novel therapeutic approach for HHT2 patients. This evidence concerns the gene GDF2 and telangiectasia, hereditary hemorrhagic, type 2.